Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC + Lenvatinib + PD-1 Inhibitor in Advanced Intrahepatic Cholangiocarcinoma
NCT07432568Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Mar 2026
- Primary completion
- Jun 2032
- Modality
- Lipid-based Nanoparticles, Orthosteric Ligands
01
Overview
A Phase 2 trial of nanoliposomal irinotecan, fluorouracil, folinic acid, lenvatinib in intrahepatic cholangiocarcinoma (ICC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
nanoliposomal irinotecanfluorouracilfolinic acidlenvatinib
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT07432568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07432568.